Active ingredientMirdametinibCat. No. P-M138-001CAS 391210-10-9Family · Pharmaceutical analytical standards
Mirdametinib
An oral MEK kinase inhibitor, approved in the United States in February 2025 and in the European Union in July 2025 for symptomatic plexiform neurofibromas in neurofibromatosis type 1, in adults and children. This family brings together the active ingredient.
Did you know?Before receiving its name it was known by the code PD-0325901; its formula contains three fluorine atoms and also an iodine atom.
Go to the active ingredient →Active ingredientMirdametinibCat. No. P-M138-001CAS 391210-10-9No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.